Neuropharmacology and pain

Francisco Ciruela Alferez / Ester Aso Pérez

PRINCIPAL INVESTIGATORS
  • Jordi Bonaventura Morera
  • Víctor Fernández Dueñas
  • África Flores de los Heros
CLINICAL RESEARCHERS
  • Pilar Hereu Boher
  • Roser Llop Rius
  • Dolores Rodríguez Cumplido
POSTDOCTORAL RESEARCHERS
  • Glòria Salort Flaquer
  • Alex Fernandez Solanas
  • Marc Lopez Cano
  • Alejandro Martín Belmonte
PREDOCTORAL RESEARCHERS
  • Laura Gómez Acero
  • Paula Alvarez Montoya
  • Nuria Sanchez Fernandez
  • Montse Flores Garcia
  • Laura Isabel Sarasola Telleria
  • Josep Argerich Bergadà
  • Thiago Carnaval
  • Arianna Rizzo
SCIENTIFIC SUPPORT
  • Aurema Otero González
  • Maria Salut Sanchez Rodriguez
VISITING RESEARCHERS
  • Kristoffer Sahlholm
  • Alessia Ligresti
Neuroscience
Neuroscience

Scientific production

26

PAPERS

Average IF: 4,81

17

LED PAPERS

Average IF: 4,2

7 PUBLICATIONS IN FIRST DECILE

15 PUBLICATIONS IN FIRST QUARTILE

20 PUBLICATIONS IN OPEN ACCESS

Selected publications:

  • López Cano,M;Scortichini,M;Tosh,DK;Salmaso,V;Ko,TG;Salort,G;Filgaira,I et al, Photoswitchable Diazocine Derivative for Adenosine A3 Receptor Activation in Psoriasis, J Am Chem Soc, 2024;147(1):874-879, doi:10.1021/jacs.4c13558
  • Argerich,J;Garma,LD;López Cano,M;Álvarez Montoya,P;Gómez Acero,L;Fernández Dueñas,V;Muñoz Manchado,AB et al, GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate., NPJ Parkinsons Dis, 2024;10(1):172-172, doi:10.1038/s41531-024-00788-x
  • Sanchez Fernández,N;Gómez Acero,L;Castañé,A;Adell,A;Campa,L;Bonaventura,J;Brito,V et al, A combination of 9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus of an animal model of Alzheimer’s disease, Neurotherapeutics, 2024;21(5):doi:10.1016/j.neurot.2024.e00439
  • Bocarsly,ME;Shaw,MJ;Ventriglia,E;Anderson,LG;Goldbach,HC;Teresi,CE;Bravo,M et al, Preexisting risk-avoidance and enhanced alcohol relief are driven by imbalance of the striatal dopamine receptors in mice, Nat. Commun., 2024;15(1):doi:10.1038/s41467-024-53414-y
  • Martín Belmonte,A;Aguado,C;Alfaro Ruiz,R;Kulik,A;de la Ossa,L;Moreno Martínez,AE;Alberquilla,S et al, Nanoarchitecture of CaV2.1 channels and GABAB receptors in the mouse hippocampus: Impact of APP/PS1 pathology, Brain Pathol, 2024;doi:10.1111/bpa.13279

Research highlights

PROJECTS

1 Granted competitive project
4 Ongoing competitive projects

1 Started clinical trial
2 Ongoing clinical trials

PUBLISHED WORKS

2 Theses

INNOVATION

1 Patent

NETWORKS

CannaLatan
COST Action 21130
COST Action CA23156

Selected projects

  • DARPA-PS-24-17. AWARE2024-DARPA – Ciruela, F. DEFENSE ADVANCED RESEARCH PROJECTS AGENCY. Budget: 203.989,72€. 2024-2026. PI: Ciruela Alférez, Francisco.
  • 2022/008797. Consecuencias de la interacción entre SARS-COV-2 y los receptores de estrógeno en las conductas adictivas. MINISTERIO DE SANIDAD Y POLITICA SO. Budget: 160.962,38€. 2023-2025. PI: BONAVENTURA MORERA, JORDI.
  • 754995. EUTRAIN: The EUropean TRAnsplantation and INnovation (EU-TRAIN) consortium for improving diagnosis and risk stratification in kidney transplant patients. COMISSIÓ EUROPEA. Budget: 68.463,44€. 2018-2024. PI: Hereu Boher, Pilar.
  • SLT017/20/000114. Subvencions per a la formació de científics i tecnòlegs: modalitat personal investigador en formació (PIF-Salut). Generalitat de Catalunya. Budget: 92.623,53€. 2021-2024. PI: Ciruela Alférez, Francisco.
  • 2024-438-1. ALTERACIONES HIDROELECTROLITICAS ASOCIADAS A FÁRMACOS. ESTUDIO DESCRIPTIVO DE LAS SOSPECHAS DE REACCIONES ADVERSAS EN UN HOSPITAL DE TERCER NIVEL. 2024- . PI: DOLORES RODRIGUEZ CUMPLIDO.